MedPath

Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort

Recruiting
Conditions
Carcinoma, Adrenocortical Recurrent
Carcinoma Adrenal
Registration Number
NCT06279442
Lead Sponsor
Latin American Cooperative Oncology Group
Brief Summary

This is a retrospective observational cohort study. The clinical, pathological and treatment data of participants identified with adrenocortical carcinoma from the year 2000 onwards will be evaluated. Participants recruited for this study will be identified at the participating sites.

Detailed Description

Adrenocortical carcinoma is one of the rarest neoplasms in the world. In Brazil, especially in the South and Southeast regions, the incidence of adrenocortical tumors is around 15 times higher than in the rest of the world, largely attributed to the significant prevalence of the TP53-R337H germline mutation in this population. In view of this characteristic, the clinical and epidemiological characterization of this cohort, as well as the identification of prognostic factors, is of great importance. The starting point for this project was the cohort of 66 participants with adrenal carcinoma included in the final project of the medical residency in clinical oncology at the A.C. Camargo Cancer Center by student Rafael Haikal dos Santos Abduch. The aim is to include case studies from the main Brazilian site that have followed up and treated patients with adrenal carcinoma.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Participants over 18 years old;
  • Diagnosis of adrenocortical carcinoma with at least one clinical evaluation at the reference institution;
  • Initial diagnosis or recurrence from the year 2000 onwards.
Exclusion Criteria
  • Participants with insufficient clinical or pathological data in the medical records.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Clinical Characterization of Adrenocortical Carcinoma in BrazilThroughout the study period, an average of 18 months.

This measure aims to capture essential clinical attributes of individuals in Brazil diagnosed with adrenocortical carcinoma. It will include relevant clinical factors such as tumor stage, hormone secretion status, and treatment modalities. These insights will contribute to a comprehensive understanding of the clinical landscape of adrenocortical carcinoma within the Brazilian population.

Demographic Characterization of Adrenocortical Carcinoma in BrazilThroughout the study period, an average of 18 months.

This measure aims to capture essential demographic attributes of individuals in Brazil diagnosed with adrenocortical carcinoma. It will include details such as age distribution in years, gender representation, geographic distribution, height in meters, weight in kilograms, as well as racial and ethnic demographics . These insights will contribute to a comprehensive understanding of the demographic landscape of adrenocortical carcinoma within the Brazilian population.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (10)

Pronutrir - Suporte Nutricional e Quimioterapia

🇧🇷

Fortaleza, Ceará, Brazil

Hospital Erasto Gaertner

🇧🇷

Curitiba, Paraná, Brazil

UOPECCAN - Hospital do Câncer de Cascavel

🇧🇷

Cascavel, Santa Catarina, Brazil

Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho

🇧🇷

São Luis, Maranhão, Brazil

FUNFARME - Hospital de Base de São José do Rio Preto

🇧🇷

São José do Rio Preto, São Paulo, Brazil

BP - A Beneficência Portuguesa de São Paulo

🇧🇷

São Paulo, Brazil

Hospital Santa Joana Recife (Instituto Américas PE)

🇧🇷

Recife, Pernambuco, Brazil

A.C. Camargo Cancer Center

🇧🇷

São Paulo, Brazil

INCA - Instituto Nacional de Câncer

🇧🇷

Rio de Janeiro, Brazil

HAOC - Hospital Alemão Oswaldo Cruz

🇧🇷

São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath